Variance in Pneumocystis jirovecii prophylaxis practice for pediatric patients undergoing hematopoietic cell transplantation
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.31201 ↗At a glance
Multizentrische Studie in Pediatric Blood & Cancer, 2024. Written by Amanda Lipsitt and 5 co-authors. Institution: Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Major MEDLINE topics: Hematopoietic Stem Cell Transplantation, Pneumocystis carinii, Pneumonia, Pneumocystis. 12 references. The full text is freely available in PubMed Central. Funded by: American Lebanese Syrian Associated Charities, NCI NIH HHS, NHLBI NIH HHS.
Abstract (original language)
Pneumocystis jirovecii pneumonia (PJP) in hematopoietic cell transplant (HCT) recipients can be prevented by efficient prophylaxis. We surveyed HCT centers in North America to assess their PJP prophylaxis practices. Most institutions used intravenous (IV) pentamidine (29.6%) or inhaled pentamidine (14.8%); 37% institutions changed from trimethoprim/sulfamethoxazole (TMP‐SMX) to another medication after conditioning; and 44% administered no PJP prophylaxis during the pre‐engraftment period. Most institutions avoided using TMP‐SMX during the pre‐engraftment period, mainly because of concerns about myelotoxicity, despite this being the preferred PJP prophylaxis agent. There is a need to evaluate the effects of TMP‐SMX on engraftment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
ORCID profiles: Akshay Sharma
Funding
- American Lebanese Syrian Associated Charities
- NCI NIH HHS
- NHLBI NIH HHS
- National Institutes of Health (NIH)/National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute
Cite
APA
Lipsitt, A., Hijano, D. R., Ferrolino, J. A., Dallas, R., Sharma, A., & Maron, G. (2024). Variance in Pneumocystis jirovecii prophylaxis practice for pediatric patients undergoing hematopoietic cell transplantation. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31201
Vancouver
Lipsitt A, Hijano DR, Ferrolino JA, Dallas R, Sharma A, Maron G. Variance in Pneumocystis jirovecii prophylaxis practice for pediatric patients undergoing hematopoietic cell transplantation. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31201
BibTeX
@article{Lipsitt2024,
author = {Lipsitt, Amanda and Hijano, Diego R and Ferrolino, Jose A and Dallas, Ronald and Sharma, Akshay and Maron, Gabriela},
title = {Variance in Pneumocystis jirovecii prophylaxis practice for pediatric patients undergoing hematopoietic cell transplantation},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.31201}
}
EUVIMED